These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 37953075)
1. Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis. Shimizu H; Nishimura Y; Shiide Y; Akimoto M; Yashiro M; Ueda M; Hirai M; Yoshino H; Mizutani T; Kanai K; Kano O; Kimura H; Sekino H; Ito K Clin Ther; 2023 Dec; 45(12):1251-1258. PubMed ID: 37953075 [TBL] [Abstract][Full Text] [Related]
2. Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects. Shimizu H; Nishimura Y; Shiide Y; Yoshida K; Hirai M; Matsuda M; Nakamaru Y; Kato Y; Kondo K Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1188-1197. PubMed ID: 33955162 [TBL] [Abstract][Full Text] [Related]
3. Edaravone Oral Suspension: A Neuroprotective Agent to Treat Amyotrophic Lateral Sclerosis. Singh P; Belliveau P; Towle J; Neculau AE; Dima L Am J Ther; 2024 May-Jun 01; 31(3):e258-e267. PubMed ID: 38691665 [TBL] [Abstract][Full Text] [Related]
4. Edaravone Administered Orally and Via Nasogastric Tube in Healthy Adults: A Comparative Bioavailability Phase 1 Study. Shimizu H; Nishimura Y; Shiide Y; Ueda M; Yokota S; Kato Y; Hirai M Clin Pharmacol Drug Dev; 2023 Jan; 12(1):77-84. PubMed ID: 36225132 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of Pharmacokinetics, Safety, and Drug-Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults. Shimizu H; Nishimura Y; Shiide Y; Matsuda H; Akimoto M; Matsuda M; Nakamaru Y; Kato Y; Kondo K Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1174-1187. PubMed ID: 33704925 [TBL] [Abstract][Full Text] [Related]
6. Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics. Dash RP; Babu RJ; Srinivas NR Clin Pharmacokinet; 2018 Nov; 57(11):1385-1398. PubMed ID: 29682695 [TBL] [Abstract][Full Text] [Related]
7. Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment. Genge A; Pattee GL; Sobue G; Aoki M; Yoshino H; Couratier P; Lunetta C; Petri S; Selness D; Bidani S; Hirai M; Sakata T; Salah A; Apple S; Wamil A; Kalin A; Jackson CE Muscle Nerve; 2023 Feb; 67(2):124-129. PubMed ID: 36504406 [TBL] [Abstract][Full Text] [Related]
8. Oral Edaravone - Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis. Pattee GL; Genge A; Couratier P; Lunetta C; Sobue G; Aoki M; Yoshino H; Jackson CE; Wymer J; Salah A; Nelson S Expert Rev Neurother; 2023; 23(10):859-866. PubMed ID: 37646130 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. ; Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181 [TBL] [Abstract][Full Text] [Related]
10. Food Effect Study to Assess the Impact on Edaravone Pharmacokinetic Profiles in Healthy Participants. Shimizu H; Nishimura Y; Shiide Y; Akimoto M; Matsuda H; Kato Y; Hirai M Clin Ther; 2022 Dec; 44(12):1552-1565. PubMed ID: 36376130 [TBL] [Abstract][Full Text] [Related]
11. Edaravone: a new hope for deadly amyotrophic lateral sclerosis. Bhandari R; Kuhad A; Kuhad A Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226 [TBL] [Abstract][Full Text] [Related]
12. Edaravone for the treatment of amyotrophic lateral sclerosis. Yoshino H Expert Rev Neurother; 2019 Mar; 19(3):185-193. PubMed ID: 30810406 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis. Luo L; Song Z; Li X; Huiwang ; Zeng Y; Qinwang ; Meiqi ; He J Neurol Sci; 2019 Feb; 40(2):235-241. PubMed ID: 30483992 [TBL] [Abstract][Full Text] [Related]
14. Logistics and safety of edaravone treatment for amyotrophic lateral sclerosis: experience in Argentina. Quarracino C; Bendersky M; Rey R; Rodríguez GE Acta Neurol Belg; 2021 Dec; 121(6):1519-1523. PubMed ID: 32436077 [TBL] [Abstract][Full Text] [Related]
15. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. Witzel S; Maier A; Steinbach R; Grosskreutz J; Koch JC; Sarikidi A; Petri S; Günther R; Wolf J; Hermann A; Prudlo J; Cordts I; Lingor P; Löscher WN; Kohl Z; Hagenacker T; Ruckes C; Koch B; Spittel S; Günther K; Michels S; Dorst J; Meyer T; Ludolph AC; JAMA Neurol; 2022 Feb; 79(2):121-130. PubMed ID: 35006266 [TBL] [Abstract][Full Text] [Related]
16. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning. Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Todorovic V; Greis T; Kondo K Clin Ther; 2020 Aug; 42(8):1467-1482.e4. PubMed ID: 32800532 [TBL] [Abstract][Full Text] [Related]
17. Riluzole Oral Suspension: Bioavailability Following Percutaneous Gastrostomy Tube-modeled Administration Versus Direct Oral Administration. Brooks BR; Bettica P; Cazzaniga S Clin Ther; 2019 Dec; 41(12):2490-2499. PubMed ID: 31635890 [TBL] [Abstract][Full Text] [Related]
18. Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System. Vu M; Tortorice K; Zacher J; Dong D; Hur K; Zhang R; Good CB; Glassman PA; Cunningham FE JAMA Netw Open; 2020 Oct; 3(10):e2014645. PubMed ID: 33017028 [TBL] [Abstract][Full Text] [Related]
19. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients. Park JM; Kim SY; Park D; Park JS Neurol Sci; 2020 Jan; 41(1):119-123. PubMed ID: 31471712 [TBL] [Abstract][Full Text] [Related]
20. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Jaiswal MK Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]